title: Practical recommendations on incorporating new oral anticoagulants into routine practice.
abstract: The use of new oral anticoagulants (NOACs) is expected to rise significantly in upcoming years. Therefore, it is important to understand the potential uses, side effects, and management of these agents in routine practice. NOACs have major pharmacologic advantages over warfarin, including a rapid onset and offset of action, fewer drug interactions, and predictable pharmacokinetics. These agents are gaining popularity among both physicians and patients because of their ease of administration and the advantage of eliminating the requirement for regular coagulation monitoring. NOACs work to prevent and treat thrombosis by targeting either thrombin (as with dabigatran) or factor Xa (as with rivaroxaban and apixaban). In this review, we discuss practical recommendations for the use of NOACs and the risks and benefits of incorporating them into routine practice.
authors: University of Cincinnati, Cincinnati, OH.
authors: Jaskirat
authors: J
authors: Randhawa
authors: Fairview/Cleveland Clinic Hospital, Cleveland, OH.
authors: Nirosshan
authors: N
authors: Thiruchelvam
authors: Fairview/Cleveland Clinic Hospital, Cleveland, OH.
authors: Michael
authors: M
authors: Ghobrial
authors: Moll Cancer Center at the Cleveland Clinic, Cleveland, OH.
authors: Timothy
authors: T
authors: Spiro
authors: Moll Cancer Center at the Cleveland Clinic, Cleveland, OH.
authors: Bernadette
authors: B
authors: Clark
authors: Moll Cancer Center at the Cleveland Clinic, Cleveland, OH.
authors: Abdo
authors: A
authors: Haddad
authors: Moll Cancer Center at the Cleveland Clinic, Cleveland, OH.
authors: Hamed
authors: H
authors: Daw
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran